JP2022530044A5 - - Google Patents

Info

Publication number
JP2022530044A5
JP2022530044A5 JP2021562977A JP2021562977A JP2022530044A5 JP 2022530044 A5 JP2022530044 A5 JP 2022530044A5 JP 2021562977 A JP2021562977 A JP 2021562977A JP 2021562977 A JP2021562977 A JP 2021562977A JP 2022530044 A5 JP2022530044 A5 JP 2022530044A5
Authority
JP
Japan
Prior art keywords
tumor
optionally
composition
vaccination
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530044A (ja
Filing date
Publication date
Priority claimed from PCT/NL2019/050451 external-priority patent/WO2020017962A1/en
Application filed filed Critical
Priority claimed from PCT/IB2020/053898 external-priority patent/WO2020217226A1/en
Publication of JP2022530044A publication Critical patent/JP2022530044A/ja
Publication of JP2022530044A5 publication Critical patent/JP2022530044A5/ja
Pending legal-status Critical Current

Links

JP2021562977A 2019-04-25 2020-04-24 腫瘍ワクチン接種方法 Pending JP2022530044A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19170999.7 2019-04-25
EP19170999 2019-04-25
NLPCT/NL2019/050451 2019-07-16
PCT/NL2019/050451 WO2020017962A1 (en) 2018-07-16 2019-07-16 A combination product for use in tumor vaccination.
US202062961554P 2020-01-15 2020-01-15
US62/961,554 2020-01-15
PCT/IB2020/053898 WO2020217226A1 (en) 2019-04-25 2020-04-24 Methods of tumor vaccination

Publications (2)

Publication Number Publication Date
JP2022530044A JP2022530044A (ja) 2022-06-27
JP2022530044A5 true JP2022530044A5 (https=) 2023-04-28

Family

ID=72941340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562977A Pending JP2022530044A (ja) 2019-04-25 2020-04-24 腫瘍ワクチン接種方法

Country Status (6)

Country Link
US (2) US11052144B2 (https=)
EP (1) EP3958894A1 (https=)
JP (1) JP2022530044A (https=)
AU (1) AU2020264083A1 (https=)
CA (1) CA3133410A1 (https=)
WO (1) WO2020217226A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
GB201919316D0 (en) * 2019-12-24 2020-02-05 Queens Univ Of Belfast Polymeric nanoparticles for enhanced cancer treatment
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CA3196677A1 (en) * 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
JP2024506249A (ja) * 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6398748B1 (en) 1999-03-16 2002-06-04 Robert B. Wilson Splint bandage and method
AU7116800A (en) 1999-09-09 2001-04-10 American Express Travel Related Services Company, Inc. System and method for authenticating a web page
WO2001049317A2 (en) 2000-01-05 2001-07-12 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
PT1346059E (pt) 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
EP1339862B1 (en) 2000-11-29 2014-01-08 PCI Biotech AS Photochemical internalization for virus-mediated molecule delivery into the cytosol
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US20040057935A1 (en) 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
JP2006232761A (ja) 2005-02-25 2006-09-07 Osaka Univ 制癌剤
AU2006260240B2 (en) 2005-06-21 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Therapeutic agent for cancer
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009127988A1 (en) 2008-04-16 2009-10-22 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2009019320A2 (en) 2008-05-19 2009-02-12 Dcprime B.V. Method for inducing and accelerating cells
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
CN103179952B (zh) 2010-09-02 2015-06-03 斯克里普斯研究学院 基于纳米颗粒的肿瘤靶向药物递送
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
NL2009102C2 (en) 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US9974848B2 (en) * 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
BR112019001115A2 (pt) 2016-07-21 2019-06-25 Vac4All Pte Ltd proteínas de biofusão como vacinas anti-malária
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.

Similar Documents

Publication Publication Date Title
JP2022530044A5 (https=)
Barbier et al. The clinical progress of mRNA vaccines and immunotherapies
JP6731405B2 (ja) ウイルス粒子を用いた癌免疫療法
Yata et al. DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy
US12533410B2 (en) Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines
DE69834494T2 (de) Vorrichtung zur induktion einer ctl-antwort
JP2021531345A5 (https=)
Xiang et al. Promising particle-based vaccines in cancer therapy
JP2015516496A5 (https=)
CN114617972B (zh) 一种药物组合物及其应用
TWI705972B (zh) 惡性病變的組合治療
CN113924091A (zh) 治疗肿瘤的方法
WO2005084387A3 (en) Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
CN119925298A (zh) 一种线粒体功能障碍仿生纳米药物及其制备和应用
JP2020182486A5 (https=)
Yang et al. Oncolytic virus for cancer immunotherapy
CN118076377A (zh) 人类表皮生长因子第二型受体疫苗组成物
JP2024529457A5 (https=)
EP4196157A1 (en) Compositions for treating gastrointestinal adenocarcinomas by altering the tumor microenvironment
US20210402006A1 (en) Nanoparticles and uses thereof
CN106344930B (zh) 分子定点靶向和激活的短肽阿霉素的制备和用途
US20210154296A1 (en) Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients
US12433840B2 (en) Melt processed viral nanoparticle constructs
KR100825984B1 (ko) 조사된 인간 ｂ형 간염 표면 항원을 발현하는 암세포를이용하여 종양을 치료하는 방법 및 상기 암세포를 포함하는종양치료용 약학적 조성물
CN115715803A (zh) 溶瘤病毒和免疫相关药物在协同抑制实体瘤中的应用